More recent preclinical studies have demonstrated that liraglutide may inhibit proliferation and migration in papillary thyroid carcinoma cell lines, potentially via PI3K/Akt/mTOR pathway modulation [29]. The gene discussed is AKT1; the disease is thyroid gland papillary carcinoma.